NovoCure (NSDQ:NVCR) today released long-term analysis data from the phase 3 pivotal EF-14 trial of its Optune device in combination with temozolomide for treating newly diagnosed glioblastoma, touting superior survival results.
Data from the trial indicated superior 2, 3 and 4-year survival rates for patients treated with the combined therapy over temozolomide alone.
Data from the study is slated to be presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in Scottsdale, Ariz. this week.
“The long-term analysis further supports our data showing that Optune together with temozolomide is a better treatment option for newly diagnosed GBM patients compared to temozolomide alone. We believe these results will give health care providers further confidence in our therapy and transform the standard of care in newly diagnosed GBM. Our priority is to improve the lives of GBM patients, and we believe these results will help us to accomplish our mission,” CEO Asaf Danziger said in prepared remarks.
Patients treated with the combined therapy reported a significant increase in median progression free survival, at 6.7 months versus 4 for those treated with the drug alone. They also reported an increase in median overall survival, at 20.8 months versus 16 months for the drug alone.
A total of 43% of patients treated with the combined therapy were alive at 2 years, versus 30% with the drug alone. Seventeen percent lived to 4 years, versus 10% with the drug alone, according to the study.
“The analysis of the full dataset confirms the improvement in both progression free and overall survival we saw in the trial’s interim analysis, and demonstrates superior long-term survival. These mature results further validate Optune as a standard of care treatment option for glioblastoma, providing patients with a therapy that can extend their survival while maintaining their quality of life,” principal investigator Dr. Roger Stupp said in a prepared statement.
Increases in progression free survival and overall survival rates were seen across all patient subgroups, across spectrums of age, performance status and tumor genetics.
“We are excited that Novocure’s long-term analysis of the EF-14 trial confirms the interim analysis results of superior overall and progression free survival, while providing new data on potential long-term survival benefits for newly diagnosed GBM patients. GBM patients need better treatment options, and it is a great day when new evidence shows that we are making progress in treating this disease,” American Brain Tumor Association prez & CEO Elizabeth Wilson said in a press release.